8-K: Brainstorm Cell Therapeutics Announces Management Changes, Prepares for Phase 3b Trial

Brainstorm Cell Therapeutics announced the promotion of Dr. Bob Dagher to Chief Medical Officer and the transition of Dr. Stacy Lindborg from Co-CEO to a board member as the company prepares for a Phase 3b trial of NurOwn.

Summary

• Brainstorm Cell Therapeutics has announced that Dr. Stacy Lindborg will step down as Co-Chief Executive Officer, effective May 9, 2024, and will join the Board of Directors on the same date.
• Dr. Lindborg's resignation is not due to any disagreements with the company or its board.
• The company has entered into a separation agreement with Dr. Lindborg, which includes a $300,000 separation bonus to be paid by March 15, 2025.
• Dr. Lindborg's unvested equity awards, except for a March 2024 grant of 241,935 restricted shares, will be forfeited.
• The March 2024 restricted stock award will continue to vest while Dr. Lindborg is a board member and will fully vest upon a change of control of the company.
• Dr. Ibrahim B. Dagher has been promoted to Executive Vice President and Chief Medical Officer, effective April 16, 2024.
• These management changes are occurring as the company prepares for a registrational Phase 3b trial for NurOwn, its investigational cell therapy for ALS.
• Dr. Lindborg will receive an initial grant of 6,666 restricted shares and an annual award of either 6,666 shares of restricted stock or a nonqualified stock option to purchase 6,666 shares for her service on the board.

Sentiment

Score: 7

Explanation: The document reflects a positive transition with key personnel changes and a clear focus on the upcoming Phase 3b trial. While there is a change in leadership, the retention of Dr. Lindborg on the board and the promotion of Dr. Dagher are viewed positively. The company's progress towards a pivotal trial is also a positive sign.

Positives

• Dr. Lindborg's continued involvement as a board member provides continuity and strategic insight.
• Dr. Dagher's promotion to Chief Medical Officer brings his extensive experience in clinical research and development to the forefront.
• The company has reached an agreement with the FDA for a Special Protocol Assessment (SPA) for the Phase 3b trial of NurOwn.
• The company is moving forward with a pivotal Phase 3b trial for NurOwn, which is a significant step towards potential regulatory approval.

Negatives

• The departure of a Co-CEO, even with a transition to the board, can create uncertainty.
• Dr. Lindborg's unvested equity awards, except for the March 2024 grant, will be forfeited.

Risks

• The company's ability to successfully conduct and complete the Phase 3b trial is subject to inherent risks and uncertainties.
• The company's future success depends on the regulatory approval of NurOwn.
• The company's ability to raise additional capital is a risk factor.
• There are risks associated with the company's ability to continue as a going concern.

Future Outlook

The company is preparing to embark on a registrational Phase 3b trial for NurOwn, and management believes the company is well-positioned for a smooth transition into this pivotal phase. The company is also working towards regulatory approval of NurOwn.

Management Comments

• Chaim Lebovits stated that Brainstorm is well positioned for a smooth transition into a pivotal phase for the company and continued commitment to ALS.
• Chaim Lebovits noted that Dr. Dagher's capabilities make him exceptionally qualified to lead the Phase 3b trial of NurOwn.
• Dr. Dagher expressed his honor to step into the role of Chief Medical Officer and his commitment to the company's mission.
• Dr. Lindborg stated her belief in the company's mission and commitment to ALS and her confidence in Dr. Dagher as the leader of the Phase 3b program.
• Mr. Lebovits thanked Dr. Lindborg for her outstanding commitment and achievements at Brainstorm.

Industry Context

The announcement comes as the biotechnology industry continues to focus on developing treatments for neurodegenerative diseases like ALS. The company's progress with NurOwn is being closely watched by investors and the medical community.

Comparison to Industry Standards

• The transition of a Co-CEO to a board position is not uncommon in the biotech industry, often done to retain expertise while adjusting leadership roles.
• The appointment of a Chief Medical Officer with extensive experience in clinical trials is a standard practice for companies advancing drug candidates through clinical development.
• The company's focus on a Phase 3b trial for NurOwn is consistent with the regulatory pathway for bringing new therapies to market.
• Other companies developing ALS treatments include Amylyx Pharmaceuticals with Relyvrio, and Biogen with Tofersen, both of which have faced regulatory hurdles and market challenges.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the company's progress towards a Phase 3b trial and the appointment of a new Chief Medical Officer.
• Employees may experience a period of transition with the change in leadership.
• Patients and families affected by ALS may be hopeful about the potential of NurOwn.

Next Steps

• The company will proceed with the Phase 3b trial of NurOwn.
• Dr. Lindborg will transition to the Board of Directors on May 9, 2024.
• Dr. Dagher will assume his new role as Executive Vice President and Chief Medical Officer.

Key Dates

Keywords

NurOwn, ALS, Phase 3b trial, Chief Medical Officer, Board of Directors, Management Changes, Stem Cell Therapy, Biotechnology, Clinical Trial, FDA